drugset / Trial / NCT03128320
The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure
RandomizedCrossoverTriple-blindOther
Summary
The purpose of the study is to analyse skin blood flow in diabetic patients. The patients receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397. The analysis of safety and tolerability are secondary objectives of this study.
Timeline
- Start
- 2017-05-25
- Primary completion
- 2019-09-06
- Completion
- 2019-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1193397 | Unknown | 1 mg | Oral |
| Subject | BAY1193397 | Unknown | 5 mg | Oral |
Indications
No indication recorded.